Precision medicine in pediatric severe asthma: Targeted blockade of type 2 inflammation.
Where this comes from
- Record sourced from PubMed, PMID 35492881.
- Also identified by DOI 10.1016/j.xcrm.2022.100570 and PMC identifier 9040171.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
A study by Bacharier et al. demonstrated that children with uncontrolled moderate-to-severe asthma with elevated type 2 biomarkers who received dupilumab had fewer exacerbations and better lung function.<sup>1</sup> These results highlight precision medicine approaches in pediatric asthma.
Medical subject headings
- Anti-Asthmatic Agents
- Asthma